James D Pancook

US Patent:

6989261, Jan 24, 2006

Filed:

Apr 11, 2003

Appl. No.:

10/413432

Inventors:

Jeffry D. Watkins - Encinitas CA, US
James D. Pancook - San Diego CA, US

Assignee:

Eli Lilly and Company - Indianapolis IN

International Classification:

C12N 9/16
C12N 9/18
C12N 1/20
C12N 15/00
C07H 21/04

US Classification:

435196, 435197, 4352523, 4353201, 536 232, 424 946

Abstract:

The invention provides a butyrylcholinesterase variant having increased cocaine hydrolysis activity as well as the corresponding encoding nucleic acid. The invention further provides methods of hydrolyzing a cocaine-based butyrylcholinesterase substrate as well as methods of treating a cocaine-induced condition with the invention variant.

US Patent:

7049121, May 23, 2006

Filed:

Dec 20, 2002

Appl. No.:

10/324466

Inventors:

Jeffry D Watkins - Encinitas CA, US
James D Pancook - San Diego CA, US

Assignee:

Applied Molecular Evolution - San Diego CA

International Classification:

C12N 9/16
C12N 9/18
C12N 1/20
C12N 15/00
C07H 21/04

US Classification:

435196, 435197, 4352523, 435320, 435325, 536 232

Abstract:

The invention provides twenty-one butyrylcholinesterase variants having increased cocaine hydrolysis activity as well as the corresponding encoding nucleic acids. The invention further provides methods of hydrolyzing a cocaine-based butyrylcholinesterase substrate as well as methods of treating a cocaine-induced condition.

US Patent:

7494651, Feb 24, 2009

Filed:

Dec 20, 2006

Appl. No.:

12/096383

Inventors:

Bryan Edward Jones - Carmel IN, US
James D. Pancook - San Diego CA, US
Scott William Rowlinson - Zionsville IN, US

Assignee:

Eli Lilly and Company - Indianapolis IN

International Classification:

A61K 39/395
C07K 16/22

US Classification:

4241451, 4241301, 4241331, 4241411, 4241521, 4241581, 5303871, 5303873, 5303882, 53038824

Abstract:

The present invention provides very high affinity antibodies, or antigen-binding fragments thereof, that neutralize mature human TGF-β1, TGF-β2, and TGF-β3. The antibodies of the invention are useful for treating cell proliferative disorders in a mammal.

US Patent:

7927593, Apr 19, 2011

Filed:

Jan 26, 2010

Appl. No.:

12/693722

Inventors:

Bryan Edward Jones - Carmel IN, US
James David Pancook - San Diego CA, US
Scott William Rowlinson - Zionsville IN, US

Assignee:

Eli Lilly and Company - Indianapolis IN

International Classification:

A61K 39/395
C07K 16/22

US Classification:

4241451, 4241301, 4241331, 4241411, 4241521, 4241581, 5303871, 5303873, 5303882, 53038824

Abstract:

The present invention provides very high affinity antibodies, or antigen-binding fragments thereof, that neutralize mature human TGF-β1, TGF-β2, and TGF-β3. The antibodies of the invention are useful for treating cell proliferative disorders in a mammal.

US Patent:

20030153062, Aug 14, 2003

Filed:

Dec 20, 2001

Appl. No.:

10/032233

Inventors:

Jeffry Watkins - Encinitas CA, US
James Pancook - San Diego CA, US

International Classification:

C07H021/04
A61K038/46
C12N009/16

US Classification:

435/196000, 424/094600, 536/023200

Abstract:

The invention provides twenty-one butyrylcholinesterase variants having increased cocaine hydrolysis activity as well as the corresponding encoding nucleic acids. The invention further provides methods of hydrolyzing a cocaine-based butyrylcholinesterase substrate as well as methods of treating a cocaine-induced condition.

US Patent:

20050136044, Jun 23, 2005

Filed:

Dec 4, 2003

Appl. No.:

10/728723

Inventors:

Jeffry Watkins - Encinitas CA, US
James Pancook - San Diego CA, US

International Classification:

A61K038/46
C07H021/04
C12P017/18
C12N009/18

US Classification:

424094600, 435197000, 435119000, 514283000, 536023200, 424178100, 530388260

Abstract:

The invention provides a butyrylcholinesterase variant having the amino acid sequence selected from SEQ ID NOS: 4, 6, 8, 10, 12, 14, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60, 62, 64, 66, 68, 70, 72, 74, 76, 78, 80, 82, 84, 86, 88, 90, 92, 94, 96, 98, 100, 102, 104, 106, 108, 110, 112, 114, 116, 118, 120, 122, 124, 126, 128, 130, 132, 134, 136, 138, 140, 142, 144, 146, 148, 150, 152, 154, 156, 158, 160, 162, 164, 166, 168, 170, 172, 174, 176, 178, 180, 182, 184, 186, 188, 190, 192, 194, and 196, or functional fragment thereof. In addition, the invention provides a method of converting a camptothecin derivative to a topoisomerase inhibitor by contacting the camptothecin derivative with a butyrylcholinesterase variant selected from SEQ ID NOS: 2, 4, 6, 8, 10, 12, 14, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60, 62, 64, 66, 68, 70, 72, 74, 76, 78, 80, 82, 84, 86, 88, 90, 92, 94, 96, 98, 100, 102, 104, 106, 108, 110, 112, 114, 116, 118, 120, 122, 124, 126, 128, 130, 132, 134, 136, 138, 140, 142, 144, 146, 148, 150, 152, 154, 156, 158, 160, 162, 164, 166, 168, 170, 172, 174, 176, 178, 180, 182, 184, 186, 188, 190, 192, 194, and 196, or functional fragment thereof, under conditions that allow conversion of a camptothecin derivative to a topoisomerase inhibitor. Further, the invention provides a method of treating cancer by administering to an individual an effective amount of a butyrylcholinesterase variant selected from SEQ ID NO: 2, 4, 6, 8, 10, 12, 14, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60, 62, 64, 66, 68, 70, 72, 74, 76, 78, 80, 82, 84, 86, 88, 90, 92, 94, 96, 98, 100, 102, 104, 106, 108, 110, 112, 114, 116, 118, 120, 122, 124, 126, 128, 130, 132, 134, 136, 138, 140, 142, 144, 146, 148, 150, 152, 154, 156, 158, 160, 162, 164, 166, 168, 170, 172, 174, 176, 178, 180, 182, 184, 186, 188, 190, 192, 194, and 196, or functional fragment thereof, exhibiting increased capability to convert a camptothecin derivative to a topoisomerase inhibitor compared to butyrylcholinesterase.

US Patent:

20060263345, Nov 23, 2006

Filed:

Apr 9, 2004

Appl. No.:

10/549006

Inventors:

Jeffry Watkins - Encinitas CA, US
James Pancook - San Diego CA, US

International Classification:

A61K 38/46
C07H 21/04
C12P 21/06
C12N 9/18

US Classification:

424094600, 435197000, 435069100, 435320100, 435325000, 536023200

Abstract:

The invention provides a butyrylcholinesterase variant having increased cocaine hydrolysis activity as well as the corresponding encoding nucleic acid. The invention further provides methods of hydrolyzing a cocaine-based butyrylcholinesterase substrate as well as methods of treating a cocaine-induced condition with the invention variant.

US Patent:

20090155285, Jun 18, 2009

Filed:

Feb 6, 2009

Appl. No.:

12/366664

Inventors:

Bryan Edward Jones - Carmel IN, US
James D. Pancook - San Diego CA, US
Scott William Rowlinson - Zionsville IN, US

International Classification:

A61K 39/395

US Classification:

4241451

Abstract:

The present invention provides very high affinity antibodies, or antigen-binding fragments thereof, that neutralize mature human TGF-β1, TGF-β2, and TGF-β3. The antibodies of the invention are useful for treating cell proliferative disorders in a mammal.